In Brief: Biopool
This article was originally published in The Gray Sheet
Biopool: Receives FDA 510(k) clearance for its Spectrolyse Antithrombin-III (anti-Xa) Assay Kit for clinically testing a "patient's risk for developing blood clots." The kit measures plasma levels of Antithrombin-III, an inhibitor of enzymes that promote the formation of blood clots. Approval of the test expands Biopool's "line of in vitro products dedicated to assessing and diagnosing the risks of clotting and bleeding disorders," the company says...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.